News

A cell-based study found that a group of experimental drugs designed to restore missing protein production in junctional epidermolysis bullosa (JEB) showed different responses to specific mutations in the COL17A1 gene, a finding researchers said could be used to work toward tailored treatment approaches. The researchers also identified a…

Zevaskyn (prademagene zamikeracel), a gene therapy approved in the U.S. last year to treat the fragile skin disease recessive dystrophic epidermolysis bullosa (RDEB), can now be administered at University of Florida Health, a university-affiliated clinic in Gainesville. That’s according to Abeona Therapeutics, the company that markets Zevaskyn, which…

Children with severe epidermolysis bullosa (EB) who take fiber or iron supplements are likely to take laxatives as well,  a retrospective study in the U.K. found. “Total fibre intake did not reduce the reliance on laxatives or improve stool consistency and frequency in children and adolescents with EB,” the…

Inmune Bio plans to submit regulatory applications in the U.K., U.S., and European Union seeking approval of Ebstrocel, its experimental stem cell therapy for recessive dystrophic epidermolysis bullosa (RDEB). The company expects to file its application in the U.K. before the end of this year, followed by…

Caring for a child with epidermolysis bullosa (EB) is often logistically challenging, socially fraught, and emotionally exhausting, a new Spanish study underscores. Based on the findings, researchers are calling for more proactive support to be given to families affected by EB. “The findings highlight the need for a more…

Children with recessive dystrophic epidermolysis bullosa (RDEB) and their parents reported less pain and itch, better wound healing, and greater participation in daily activities after treatment with Inmune Bio’s Ebstrocel, an experimental stem cell therapy, during the MissionEB trial, according to a new analysis. The findings build on…

Inmune Bio has assembled a scientific advisory board to help guide its development of Ebstrocel, a stem cell therapy designed to promote wound healing in people with the fragile skin disease RDEB, fully recessive dystrophic epidermolysis bullosa. The newly formed advisory board will provide Inmune with advice ranging…

A U.S.-based biotech company announced that it has reached a “significant” milestone in advancing its experimental stem cell treatment for recessive dystrophic epidermolysis bullosa (RDEB), a rare condition marked by extremely fragile skin. Inmune Bio said it has readied its process for commercial-grade manufacturing of CORDStrom, the stem…

A new biotechnology company called Rinascera Therapeutics has launched to develop therapies for people with epidermolysis bullosa and other rare genetic skin diseases. The company is working to advance two treatment candidates. RIN-002 is being developed for dystrophic epidermolysis bullosa (DEB), while RIN-001 is being developed for another…

A young girl with genetically confirmed epidermolysis bullosa simplex experienced a marked reduction in skin blistering — with no new sores for several months — with use of isotretinoin, an oral medication derived from vitamin A, according to a new case report. Its researchers say the child’s case…

Biomendics’ BM-3103, formulated as TolaSure Gel for epidermolysis bullosa simplex (EBS), has been granted fast track status by the U.S. Food and Drug Administration (FDA) for treating people with fragile skin due to EBS. The new designation could accelerate the development and review of the topical treatment if the gel…

Health Canada has granted priority review to Chiesi Global Rare Diseases’ application seeking approval of Filsuvez (birch triterpenes), a topical gel to treat skin wounds in people with dystrophic epidermolysis bullosa (DEB) or junctional epidermolysis bullosa (JEB), ages 6 months or older. Priority review is granted to therapies for…